Lifeboat Foundation

Alzheimer’s disease (AD) is a debilitating progressive illness that begins with mild memory loss and slowly destroys cognitive function and memory. It currently has no cure and is predicted to affect over 100 million people worldwide by 2050. In the United States, AD is the leading cause of dementia in older adults and the 7th most common cause of death, according to the National Institute on Aging.

Ongoing Alzheimer’s research is focused on two key neurotoxic proteins: amyloid beta (Aβ) and tau. Although these proteins have been shown to be associated with AD, the levels of Aβ and tau do not consistently explain or correlate with the severity of cognitive decline for some people with the disease.

Investigators at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, set out to identify other proteins that may be directly involved with fundamental aspects of AD, like synaptic loss and neurodegeneration. They exposed laboratory neurons to human brain extracts from about 40 people who either had AD, were protected from AD despite having high Aβ and tau levels, or were protected from AD with little or no Aβ and tau in their brains.

BioViva CEO Liz Parrish believes we can extend lifespans by extending telomeres.

Some animals do not age at all and prove that aging is not inevitable. Scientists are working on ways to slow down and even reverse aging.

The discovery that earned Japan’s Shinya Yamanaka the 2012 Nobel Prize in Medicine has paved the way for new research proving that aging is a reversible process. Currently just being tested on lab mice, will the cellular reprogramming soon offer eternal youth?

Preclinical and clinical evidence for exercise as a senescence-targeting therapy and areas needing further investigation are discussed.

(http://www.pharma.unizg.hr/en/about-us/staff/gordan–lauc, 450.html) is Professor of Biochemistry and Molecular Biology at the University of Zagreb, Faculty of Pharmacy and Biochemistry, and Founder and CEO of Genos Ltd. (https://genos-glyco.com/), a research-intensive SME located in Zagreb, Croatia with core of expertise in molecular genetics and glycomics (The comprehensive study the entire complement of sugars, whether free or present in more complex molecules of an organism) and they perform contract research, contract analysis and service for numerous universities, hospitals and private individuals in Europe and overseas.

Prof. Dr. Lauc also is CSO of GlycanAge LTD (https://glycanage.com/), a company that has developed a ground-breaking test that analyses your personal glycobiome for insights in improving your health and monitoring your biological age, and Co-Director of the Human Glycome Project (https://human-glycome.org/).

Continue reading “Prof. Dr. Gordan Lauc, Ph.D. — Founder & CEO, Genos; CSO, GlycanAge; Advancing The Glycosciences” »

Ben Goertzel, PhD, is author of many books on artificial intelligence including Ten Years to the Singularity if We Really Really Try; Engineering General Intelligence, Vols. 1 and 2; The Hidden Pattern: A Patternist Philosophy of Mind; and The Path to Posthumanity. He is also editor (with Damien Broderick) of an anthology about parapsychology titled, Evidence for Psi: Thirteen Empirical Research Reports. He is chief scientific officer for Hanson Robotics in Hong Kong.

Here he notes that, while the question of reincarnation in robots seems outlandish, most of our present technology would have seemed nonsensical and incomprehensible to earlier generations of humans. He quotes the 14th Dalai Lama who suggested (half-jokingly) that artificial intelligence programmers of the future might incarnate into robots. He cites Stephen Braude’s book, Immortal Remains, as demonstrating that we must consider some version of consciousness operating outside of the body. He outlines the sort of scientific and metaphysical models that might lead to such a development.

Continue reading “Reincarnation and Robots with Ben Goertzel” »

Occupation-related stress and work characteristics are possible determinants of social inequalities in epigenetic aging but have been little investigated. Here, we investigate the association of several work characteristics with epigenetic age acceleration (AA) biomarkers.

The study population included employed and unemployed men and women (n = 631) from the UK Understanding Society study. We evaluated the association of employment and work characteristics related to job type, job stability; job schedule; autonomy and influence at work; occupational physical activity; and feelings regarding the job with four epigenetic age acceleration biomarkers (Hannum, Horvath, PhenoAge, GrimAge) and pace of aging (DunedinPoAm, DunedinPACE).

We fitted linear regression models, unadjusted and adjusted for established risk factors, and found the following associations for unemployment (years of acceleration): HorvathAA (1.51, 95% CI 0.08, 2.95), GrimAgeAA (1.53, 95% CI 0.16, 2.90) and 3.21 years for PhenoAA (95% CI 0.89, 5.33). Job insecurity increased PhenoAA (1.83, 95% CI 0.003, 3.67), while working at night was associated with an increase of 2.12 years in GrimAgeAA (95% CI 0.69, 3.55). We found effects of unemployment to be stronger in men and effects of night shift work to be stronger in women.